Alta Life Sciences is leading a Series A round of 4 million euros to finance the clinical development of Bionure’s lead compound BN201, that has demonstrated its potential to promote neuroprotection and remyelination in the preclinical phase, offering a game-changing solution for neurodegenerative diseases. Bionure, Barcelona based biotech company that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis…
